DE69435332D1 - Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen - Google Patents
Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen TeilchenInfo
- Publication number
- DE69435332D1 DE69435332D1 DE69435332T DE69435332T DE69435332D1 DE 69435332 D1 DE69435332 D1 DE 69435332D1 DE 69435332 T DE69435332 T DE 69435332T DE 69435332 T DE69435332 T DE 69435332T DE 69435332 D1 DE69435332 D1 DE 69435332D1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- particles
- preparation
- envelope protein
- human papillomavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002245 particle Substances 0.000 title abstract 2
- 101710091045 Envelope protein Proteins 0.000 title 1
- 241000701806 Human papillomavirus Species 0.000 title 1
- 101710188315 Protein X Proteins 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 241001631646 Papillomaviridae Species 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/028,517 US8062642B1 (en) | 1993-03-09 | 1993-03-09 | Production of papillomavirus capsid protein and virus-like particles |
US20730994A | 1994-03-07 | 1994-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69435332D1 true DE69435332D1 (de) | 2011-02-17 |
Family
ID=26703787
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1994634383 Pending DE122007000014I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen |
DE69435332T Expired - Lifetime DE69435332D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen |
DE69435331T Expired - Lifetime DE69435331D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln |
DE69434383T Expired - Lifetime DE69434383T2 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE201112100018 Pending DE122011100018I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen. |
DE05075369T Pending DE05075369T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen |
DE122007000090C Pending DE122007000090I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE122007000089C Pending DE122007000089I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE05075889T Pending DE05075889T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1994634383 Pending DE122007000014I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435331T Expired - Lifetime DE69435331D1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln |
DE69434383T Expired - Lifetime DE69434383T2 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE201112100018 Pending DE122011100018I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen. |
DE05075369T Pending DE05075369T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen |
DE122007000090C Pending DE122007000090I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE122007000089C Pending DE122007000089I1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DE05075889T Pending DE05075889T1 (de) | 1993-03-09 | 1994-03-08 | Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen |
Country Status (14)
Country | Link |
---|---|
EP (3) | EP0688227B1 (de) |
JP (4) | JPH08507685A (de) |
AT (3) | ATE492289T1 (de) |
AU (3) | AU688759C (de) |
CA (1) | CA2157932C (de) |
DE (9) | DE122007000014I1 (de) |
DK (2) | DK1618888T3 (de) |
ES (3) | ES2263406T3 (de) |
FR (1) | FR11C0022I2 (de) |
HK (2) | HK1082196A1 (de) |
LU (3) | LU91313I2 (de) |
NL (3) | NL300265I2 (de) |
PT (2) | PT688227E (de) |
WO (1) | WO1994020137A1 (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7476389B1 (en) | 1991-07-19 | 2009-01-13 | The University Of Queensland | Papillomavirus vaccines |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
EP1728800A1 (de) * | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
ES2213185T3 (es) * | 1995-11-15 | 2004-08-16 | MERCK & CO., INC. | Particulas de tipo virus hpv11 sinteticas. |
DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
EP0956349B1 (de) * | 1996-10-04 | 2003-12-17 | Merck & Co., Inc. (a New Jersey corp.) | Synthetische hpv16 virus-ähnliche partikel |
WO1998025646A1 (en) * | 1996-12-09 | 1998-06-18 | Merck & Co., Inc. | Synthetic hpv16 virus-like particles |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
EP1319089B1 (de) * | 2000-09-18 | 2010-12-01 | MedImmune, LLC | In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
EP1425423B1 (de) | 2001-08-13 | 2010-06-23 | University of Rochester | Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
WO2006065166A1 (fr) * | 2005-07-26 | 2006-06-22 | Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' | Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7 |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US8778351B2 (en) | 2006-08-30 | 2014-07-15 | University Of Rochester | Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
TR201807756T4 (tr) | 2006-09-26 | 2018-06-21 | Infectious Disease Res Inst | Sentetik adjuvan içeren aşı bileşimi. |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
MX2009009342A (es) | 2007-03-02 | 2009-09-11 | Glaxosmithkline Biolog Sa | Metodo novedoso y composiciones. |
WO2008134935A1 (fr) | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
BRPI0811016B1 (pt) * | 2007-04-29 | 2021-09-21 | Xiamen Innovax Biotech Co., Ltd. | Proteína li truncada do papiloma vírus humano tipo 16 |
EP2154148B1 (de) | 2007-05-29 | 2016-06-22 | Xiamen University | Verkürztes l1-protein des humanen papillomavirus 11 |
BRPI0810951B8 (pt) | 2007-05-29 | 2021-05-25 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv |
US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
EA027784B1 (ru) | 2008-05-26 | 2017-09-29 | Кадила Хелзкэр Лимитед | Комбинированная вакцина против кори и вируса папилломы человека |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
US20120115207A1 (en) * | 2009-04-03 | 2012-05-10 | Deutsches Krebsforschungszentrum | Enhanced production of papillomavirus-like particles with a modified baculovirus expression system |
EP2437753B1 (de) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
EP3730943A1 (de) | 2010-04-08 | 2020-10-28 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Zellenassay mit b-zellen-antigenen |
AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CN104363892A (zh) | 2012-02-07 | 2015-02-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
US20150110824A1 (en) | 2012-03-18 | 2015-04-23 | Glaxosmithkline Biologicals, Sa | Method of vaccination against human papillomavirus |
RS57420B1 (sr) | 2012-05-16 | 2018-09-28 | Immune Design Corp | Vakcine za hsv-2 |
WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US11801223B2 (en) | 2013-12-31 | 2023-10-31 | Access To Advanced Health Institute | Single vial vaccine formulations |
CA3010905A1 (en) | 2016-02-22 | 2017-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Method for the immobilization of biomolecules |
CN109562057A (zh) | 2016-05-16 | 2019-04-02 | 传染病研究所 | 聚乙二醇化脂质体和使用方法 |
IL314130A (en) | 2016-05-16 | 2024-09-01 | Access To Advanced Health Inst | Formulation containing a TLR agonist and methods of use |
BR112018074352B1 (pt) | 2016-06-01 | 2021-11-30 | Infectious Disease Research Institute | Partículas de nanoalume contendo um agente de dimensionamento |
KR102673794B1 (ko) | 2017-06-15 | 2024-06-11 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
CN114340665A (zh) | 2019-05-25 | 2022-04-12 | 传染病研究所 | 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法 |
AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
WO2022171681A1 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Hpv vaccine manufacture |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
CN116375816B (zh) * | 2023-01-06 | 2023-09-05 | 北京康乐卫士生物技术股份有限公司 | 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4956288A (en) * | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
NZ232913A (en) * | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
US7476389B1 (en) * | 1991-07-19 | 2009-01-13 | The University Of Queensland | Papillomavirus vaccines |
-
1994
- 1994-03-08 DE DE1994634383 patent/DE122007000014I1/de active Pending
- 1994-03-08 DE DE69435332T patent/DE69435332D1/de not_active Expired - Lifetime
- 1994-03-08 DE DE69435331T patent/DE69435331D1/de not_active Expired - Lifetime
- 1994-03-08 EP EP94912186A patent/EP0688227B1/de not_active Expired - Lifetime
- 1994-03-08 DE DE69434383T patent/DE69434383T2/de not_active Expired - Lifetime
- 1994-03-08 JP JP6520236A patent/JPH08507685A/ja not_active Withdrawn
- 1994-03-08 ES ES05075889T patent/ES2263406T3/es not_active Expired - Lifetime
- 1994-03-08 AT AT05075889T patent/ATE492289T1/de not_active IP Right Cessation
- 1994-03-08 ES ES94912186T patent/ES2242955T4/es not_active Expired - Lifetime
- 1994-03-08 AT AT05075369T patent/ATE494005T1/de active
- 1994-03-08 EP EP05075889A patent/EP1588713B1/de not_active Expired - Lifetime
- 1994-03-08 DE DE201112100018 patent/DE122011100018I1/de active Pending
- 1994-03-08 AU AU64436/94A patent/AU688759C/en not_active Expired
- 1994-03-08 PT PT94912186T patent/PT688227E/pt unknown
- 1994-03-08 DE DE05075369T patent/DE05075369T1/de active Pending
- 1994-03-08 AT AT94912186T patent/ATE296111T1/de active
- 1994-03-08 DE DE122007000090C patent/DE122007000090I1/de active Pending
- 1994-03-08 ES ES05075369T patent/ES2263405T3/es not_active Expired - Lifetime
- 1994-03-08 DK DK05075369.8T patent/DK1618888T3/da active
- 1994-03-08 PT PT05075369T patent/PT1618888E/pt unknown
- 1994-03-08 DK DK94912186T patent/DK0688227T3/da active
- 1994-03-08 EP EP05075369A patent/EP1618888B1/de not_active Expired - Lifetime
- 1994-03-08 CA CA2157932A patent/CA2157932C/en not_active Expired - Lifetime
- 1994-03-08 DE DE122007000089C patent/DE122007000089I1/de active Pending
- 1994-03-08 DE DE05075889T patent/DE05075889T1/de active Pending
- 1994-03-08 WO PCT/US1994/002443 patent/WO1994020137A1/en active IP Right Grant
-
2006
- 2006-03-14 HK HK06103227.3A patent/HK1082196A1/xx not_active IP Right Cessation
- 2006-03-28 HK HK06103842.8A patent/HK1082206A1/xx not_active IP Right Cessation
- 2006-10-11 JP JP2006277056A patent/JP4486075B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-21 NL NL300265C patent/NL300265I2/nl unknown
- 2007-02-21 LU LU91313C patent/LU91313I2/fr unknown
- 2007-03-07 AU AU2007201006A patent/AU2007201006B2/en not_active Expired
- 2007-03-07 AU AU2007201005A patent/AU2007201005B2/en not_active Expired
- 2007-12-14 LU LU91392C patent/LU91392I2/fr unknown
- 2007-12-14 NL NL300310C patent/NL300310I1/nl unknown
- 2007-12-14 LU LU91391C patent/LU91391I2/fr unknown
- 2007-12-14 NL NL300309C patent/NL300309I2/nl unknown
-
2010
- 2010-02-05 JP JP2010023690A patent/JP5306251B2/ja not_active Expired - Lifetime
- 2010-02-05 JP JP2010023691A patent/JP5386392B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-04 FR FR11C0022C patent/FR11C0022I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69435332D1 (de) | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen | |
DK0809700T3 (da) | Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf | |
DE69535018D1 (de) | Papillomavirus vakzine | |
ATE288489T1 (de) | Vp-antigene des jc-virus | |
EP0868522A4 (de) | Rekombinantes pockenvirus der infektiösen peritonitis der katze, zusammensetzungen dessen und methoden zur herstellung und verwendung | |
DK0750669T3 (da) | Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra | |
ATE290093T1 (de) | EXPRIMIERUNG EINES MODIFIZIERTEM ßFOAMY VIRUS ENVELOPE PROTEINß (HÜLLENPROTEIN) |